Related Experiment Video
Updated: Jul 11, 2026
09:16
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Biological treatments for amfetamine dependence : recent progress
Kevin P Hill1, Mehmet Sofuoglu
1Alcohol and Drug Abuse Treatment Program, McLean Hospital, Belmont, Massachusetts 02478-9106, USA. kphill@partners.org
CNS Drugs
|September 14, 2007
Summary
Amfetamine abuse is a global epidemic, particularly methamphetamine in the US. Research explores treatments and pharmacogenetics for amfetamine dependence, offering hope for future therapies.
Area of Science:
- Neuroscience
- Pharmacology
- Addiction Medicine
Background:
- Amfetamine and methamphetamine abuse represent a significant global health crisis.
- Methamphetamine abuse has seen a notable increase in the United States since the 1960s.
- Developing effective treatments for amfetamine dependence remains a critical challenge.
Purpose of the Study:
- To review current knowledge on treatments for amfetamine dependence.
- To explore the potential of pharmacogenetics in identifying novel therapeutic targets.
- To summarize findings from animal and human studies on amfetamine abuse treatments.
Main Methods:
- A comprehensive literature search was conducted using PubMed, covering publications from 1964 to 2007.
- The review synthesized data from both animal models and human clinical studies.
- Pharmacogenetic approaches were investigated for their role in treatment development.
Main Results:
- Animal models have identified several promising therapeutic targets related to reward pathways, drug-seeking behavior, and withdrawal symptoms.
- Preclinical and some clinical results have shown promise, but clinical studies have produced inconsistent outcomes.
- Pharmacogenetics offers a potential avenue to identify genetic markers predicting treatment response.
Conclusions:
- While preclinical research is encouraging, clinical translation of amfetamine dependence treatments requires further investigation.
- Pharmacogenetic studies are crucial for personalizing treatment strategies and improving therapeutic efficacy.
- Continued research into preclinical findings and clinical progression provides optimism for developing effective amfetamine dependence treatments.
Related Concept Videos
01:17Drug Dependence
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
01:15Drug Abuse and Addiction: Pharmacological Phenomena
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...